|
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for 177Lu-PSMA therapy in advanced prostate cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb/Roche; Ipsen; MSD; Novartis; Pfizer |
Research Funding - BMS GmbH & Co. KG; Takeda |
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Roche |
|
|
Honoraria - Astellas Medivation; Janssen (Inst); MSD (Inst); Sanofi (Inst) |
Consulting or Advisory Role - Astellas Medivation; Bristol-Myers Squibb (Inst); Janssen (Inst); MSD; Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Ipsen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Wren Laboratories |